Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2026
Date Issued: August 24, 2026
Subject: Regulatory update regarding Jemperli (dostarlimab) for locally advanced rectal cancer.
Key Financial Metrics
This filing is a current report regarding a specific regulatory milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
- FDA Priority Review: The US FDA has accepted a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) for the treatment of previously untreated stage II and III mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer.
- Review Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2027.
- Expedited Pathways: The application is eligible for expedited review under the National Priority Voucher program, which could result in an earlier decision. It is also accepted under Project Orbis for coordinated international regulatory reviews.
- Clinical Data: The application is supported by the AZUR-1 phase II trial (n=154), which met its primary objective of demonstrating a sustained clinical complete response rate for 12 months (cCR12) with no detectable signs of cancer.
Outlook, Risks, and Management Commentary
Management Commentary: GSK states that if approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients, representing a substantial improvement over the historical standard of care. The safety profile observed in the trial was consistent with the drug's known profile across solid tumors.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2025 Annual Report on Form 20-F and Q2 2026 results. Regulatory decisions remain independent in each country despite the Project Orbis initiative.
Investor Verification Checklist
- Verify the final FDA decision and approval status by the February 2027 PDUFA date.
- Confirm whether the National Priority Voucher program results in an expedited decision prior to the standard timeline.
- Monitor the presentation of full AZUR-1 trial data at the upcoming scientific congress in late 2026.
- Assess the potential commercial impact of eliminating chemotherapy, radiation, and surgery for the 5-10% of rectal cancer patients with the dMMR/MSI-H subtype.
- Review the "Risk Factors" section in the 2025 Form 20-F for detailed regulatory and development risks.